VJOncology is committed to improving our service to you

ASCO 2020 | JVDF: immune profiling and clinical outcomes in patients treated with ramucirumab and pembrolizumab

VJOncology is committed to improving our service to you

Roy Herbst

Roy Herbst, MD, PhD, FACP, FASCO, of Yale University, New Haven, CT, discusses the results of the Phase I JVDF study (NCT02443324) which aimed to evaluate the effect of ramucirumab, a VEGF inhibitor, in combination with pembrolizumab. Immune profliling suggests that the inclusion of a VEGF inhibitor increases inflammation within the tumour microenvironment, which may result in increased efficacy compared to checkpoint blockade therapies alone. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter